40 Per Cent Returns from 52-Week Low; Board Announce 1:1 Bonus Shares and 30 Per Cent Dividend 40 Per Cent Returns from 52-Week Low; Board Announce 1:1 Bonus Shares and 30 Per Cent Dividend The stock is up over 40 per cent from its 52-week low of Rs 148.05 per share. DSIJ Intelligence-1 / Sunday, May 25, 2025 / Article rating: 3.6 The stock is up over 40 per cent from its 52-week low of Rs 148.05 per share.
47 Per Cent Returns from 52-Week Low; Board Likely to Announce Bonus Shares and Dividend 47 Per Cent Returns from 52-Week Low; Board Likely to Announce Bonus Shares and Dividend The stock is up by 47 per cent from its 52-week low of Rs 148.05 per share. DSIJ Intelligence-1 / Tuesday, May 20, 2025 / Article rating: 4.5 The company has a market cap of over Rs 1,000 crore and has delivered good profit growth of 19 per cent CAGR over the last 5 years with a healthy dividend payout of 26 per cent.
CuraTeQ Biologics receives approval for Biosimilar Zefylti from the UK’s MHRA CuraTeQ Biologics receives approval for Biosimilar Zefylti from the UK’s MHRA The company has a market cap of over Rs 70,000 crore and the stock is up by 24.3 per cent from its 52-week low of Rs 994.35 per share. DSIJ Intelligence-1 / Wednesday, May 14, 2025 / Article rating: 5.0 The company has a market cap of over Rs 70,000 crore and the stock is up by 24.3 per cent from its 52-week low of Rs 994.35 per share.
Pharma penny stock under Rs 40 bags new order worth USD 1,38,075 from Taha Drugs & Chemicals Co. Ltd Pharma penny stock under Rs 40 bags new order worth USD 1,38,075 from Taha Drugs & Chemicals Co. Ltd The stock is up 11.15 per cent from its 52-week low of Rs 35.70 per share.. DSIJ Intelligence-1 / Monday, May 5, 2025 / Article rating: 4.3 The stock is up 11.15 per cent from its 52-week low of Rs 35.70 per share.
Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP Aurobindo Pharma Limited announced obtaining the last approval from the US Food & Drug Administration (USFDA) for Rivaroxaban Tablets USP, 2.5 mg. DSIJ Intelligence-1 / Monday, April 14, 2025 / Article rating: 5.0 The biosimilars division alongside niche product development represents Aurobindo Pharma's main focus areas where its 1500 scientists dedicate their efforts.
Pharma Company Enters Into Share Purchase Agreement and Power Supply Agreement with Torrent Urja 19 Pvt Ltd Pharma Company Enters Into Share Purchase Agreement and Power Supply Agreement with Torrent Urja 19 Pvt Ltd The company has a market cap of over Rs 13,000 crore and the stock is up 45 per cent from its 52-week low of Rs 743.60 per share. DSIJ Intelligence-1 / Thursday, April 3, 2025 / Article rating: 4.5 The company has a market cap of over Rs 13,000 crore and the stock is up 45 per cent from its 52-week low of Rs 743.60 per share.
46 Per Cent Returns From 52-Week Low: Pharma Stock Under Rs 75, Hit 10 Per Cent Upper Circuit; Here’s Why 46 Per Cent Returns From 52-Week Low: Pharma Stock Under Rs 75, Hit 10 Per Cent Upper Circuit; Here’s Why The company has a market cap of over Rs 400 crore and the stock is up by 46 per cent from its 52-week low of Rs 50.42 per share. DSIJ Intelligence-1 / Thursday, April 3, 2025 / Article rating: 5.0 The company has a market cap of over Rs 400 crore and the stock is up by 46 per cent from its 52-week low of Rs 50.42 per share.
Emcutix and WiQo Sign Exclusive Licensing Partnership to Revolutionize Derma-cosmetic Treatments in India Emcutix and WiQo Sign Exclusive Licensing Partnership to Revolutionize Derma-cosmetic Treatments in India The stock is up by 20 per cent from its 52-week low of Rs 911.75 per share. DSIJ Intelligence-1 / Tuesday, April 1, 2025 / Article rating: 5.0 The stock is up by 20 per cent from its 52-week low of Rs 911.75 per share.
From Rs 5.82 to Rs 31.96 per share in 294 days: Pharma penny stock hit 5 per cent upper circuit on March 24 From Rs 5.82 to Rs 31.96 per share in 294 days: Pharma penny stock hit 5 per cent upper circuit on March 24 The stock gave multibagger returns of 449 per cent from its 52-week low of Rs 5.82 per share. DSIJ Intelligence-1 / Monday, March 24, 2025 / Article rating: 3.6 The stock gave multibagger returns of 449 per cent from its 52-week low of Rs 5.82 per share.
Pharma Giant Expands with Strategic Acquisition in Singapore Pharma Giant Expands with Strategic Acquisition in Singapore The company has a strong presence in regulated markets such as the United States and Europe and is a leading producer of niche generic formulations. DSIJ Intelligence-1 / Thursday, March 20, 2025 / Article rating: 4.0 The company has been actively expanding its product pipeline, with over 70 commercialized products and a healthy pipeline of 100+ approved products.